Felix Biotechnology is accelerating the development and deployment of novel biotherapeutics to treat life-threatening microbial infections in human health. Our core technology is consists of synthetic biology platforms licensed from Berkeley allowing for discovery and engineering of these novel molecules as well as a preclinical asset licensed from Yale University. Our technology has currently been deployed to treat MDR and PDR Pseudomonas aeruginosa infections in 10 cystic fibrosis patients using a compassionate use IND. These treatments have all been safe, and have positive primary and secondary clinical outcomes. We have additional candidates targeting S. aureus and MRSA infections, as well as candidates targeting Burkholderia and Acinetobacter infections. Additionally, we have some discovery biotherapeutics targeting clinically important fungal infections.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
FBTCF1 targeting MDR Pseudomonas aeruginosa infections in cystic fibrosis patients
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):